Latest Breaking News On - Corporate communications investors - Page 5 : comparemela.com

Mesoblast Limited (MESO) Receives CRL from FDA for Steroid-Refractory Acute Graft Versus Host Disease in Children

Mesoblast Limited (MESO) Receives CRL from FDA for Steroid-Refractory Acute Graft Versus Host Disease in Children
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSilviu itescuPaul hughesSteve dabkowskiMesoblast limited nasdaqAustralian securities exchangeInternational consortiumCorporate communications investorsDrug administrationMarrow transplant researchMarrow transplantation groupInternational bloodMesoblast the companyWorldwide network for bloodWhile the oncologic drugs advisory committeeMesoblast limited

Appendix 4C Quarterly Activity Report for Quarter Ended

NEW YORK, July 30, 2023 (GLOBE NEWSWIRE) Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory.

United statesSteve dabkowskiPaul hughesAustralian securities exchangeCorporate communications investorsMesoblast limited nasdaqDrug administrationPharmaceuticals coLicense applicationPrescription drug user fee actPre license inspectionNon executive directorsExecutive directorsQuarterly cash flow reportMesoblast limitedPrivate securities litigation reform act

Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2023

Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSteve dabkowskiPaul hughesCorporate communications investorsMesoblast limited nasdaqDrug administrationPharmaceuticals coAustralian securities exchangeLicense applicationPrescription drug user fee actPre license inspectionNon executive directorsExecutive directorsQuarterly cash flow reportMesoblast limitedLooking statementsthis

Mesoblast Reports Operational and Financial Highlights for

NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory.

United kingdomUnited statesSteve dabkowskiPaul hughesResearch developmentMarrow transplant researchAustralian securities exchangeCorporate communications investorsPharmaceuticals coJournal of the american college cardiologyDrug administrationMesoblast limited nasdaqBiologics license applicationPrescription drug user fee actPre license inspectionFood drug

Mesoblast Reports Operational and Financial Highlights for Quarter Ended March 31, 2023

26.05.2023 - NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) - Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights and financial results for the period ended March .

United statesUnited kingdomPaul hughesSteve dabkowskiPharmaceuticals coDrug administrationAustralian securities exchangeMarrow transplant researchResearch developmentCorporate communications investorsJournal of the american college cardiologyBiologics license applicationPrescription drug user fee actPre license inspectionFood drugCosmetic act